News

Newcastle Helix life science cluster to host virtual careers event

The Biosphere, a specialist lab facility on Newcastle Helix is hosting an online careers event aimed at graduates and postgraduate research students who are looking to make the transition from academia to industry.

The event will see representatives from a range of companies who are based in The Biosphere. They will share their own experiences, personal journey, top tips, and industry insight. They will also showcase some of the exciting job opportunities available to those looking to base themselves in North East.

Making a statement at Liverpool's Royal Albert Dock

Today we announce the completion of our permanent office space in the Edward Pavilion building in Liverpool's vibrant and iconic Royal Albert Dock.

The completion of the project follows the signing of a ten-year lease in February 2020 and underlines our long-term commitment to the city and its communities.

Since establishing a presence in Liverpool in November 2018, the firm has built a team of 100+ legal and business experts, and has a growing reputation as an employer of choice for outstanding talent in the region.

Advising Unibuddy on its US$20 million Series B investment to reinvent university recruitment

We have advised the Global EdTech startup, Unibuddy on its US$20 million Series B investment.

Unibuddy is the number one peer-to-peer university recruitment platform that has helped 770,000 students from over 180 countries make better decisions about their higher education journey. The platform works with 450+ higher education institutions worldwide, from the University of Cambridge (UK) and the University of Southern California (US) to Taylor’s University (Malaysia) and Bond University (Australia).

Membership Update July 2021

Click here

NeRRe Therapeutics raises £20 million in a Series B2 financing round

Stevenage, UK, 7 July 2021 – NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (N

Bold new life sciences vision sets path for UK to build on pandemic response and deliver life-changing innovations to patients

UK Life Sciences Vision sets 10-year strategy for sector to solve some of the biggest healthcare problems of our generation, including cancer and dementia.

Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration

Tokyo, Japan, and Cambridge, UK, 6 July 2021 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug design and development, and InveniAI® LLC (“InveniAI,” Guilford, CT, USA), a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, announced today

Taylor Wessing crowned best Private Client Law Firm

We have taken home the most coveted prize at the inaugural eprivateclient Excellence Awards.

An online black tie gala ceremony was held on 24 June to announce the awards, designed to recognise the outstanding achievements of eprivateclient’s top-ranked firms. This included firms from across the UK working in offshore legal, tax, fiduciary and advisory professional services over the last 12 months. Overall, 66 firms entered the 11 categories, with 27 contestants shortlisted.

Launching the power of LitiGate across our network

We have officially launched LitiGate's AI-driven litigation platform across our network of contentious teams.

The firm has moved from a test phase of the tool on a select number of cases, to a rollout across the wider community of contentious practices involving its application to many of the most significant pieces of litigation or arbitration.

We chose LitiGate as our go-to litigation lifecycle platform to support clients with contentious matters, following our work with the platform's developers during the testing phase.

Catalent Supports Belgium-Based Cell and Gene Therapy Accelerator

Brussels South Charleroi BioPark (BSCB) recently announced it has launched a Cell and Gene Therapy Accelerator program to de-risk early stage research and create the advanced therapy companies of the future. Open to academic, industry or independent researchers across Europe, the program consists of an intensive bootcamp, workshops and coaching, plus access to Université libre de Bruxelles (ULB) Open BioLab and state-of-the-art technology platforms.

My Account